Coffee consumption linked to reduced risk for primary sclerosing cholangitis
ORLANDO, Fla. — Coffee consumption may protect against primary sclerosing cholangitis, but not against primary biliary cirrhosis, according to data presented at Digestive Disease Week.
Researchers mailed a coffee questionnaire to 530 patients with primary biliary cirrhosis (PBC), 348 with primary sclerosing cholangitis (PSC) and 456 controls. The response rates were 78% among PBC patients, 68% among PSC patients and 77% among controls. The questionnaire included 10 questions about participants’ current and lifetime coffee consumption.
“I think we need to further assess if there are environmental factors that can help to prevent these liver disorders,” researcher Craig Lammert, MD, gastroenterology fellow at the Mayo Clinic in Rochester, Minn., told Healio.com. “These are rare disorders, but nonetheless they’re very detrimental, increasing the risk of cancer, transplant and even death. We’re looking for very simple things that are modifiable factors that may help augment someone’s genetic predisposition.”
Patients with PSC were both more likely to have never consumed coffee (21% vs. 13%) and significantly less likely to be current coffee drinkers (67% vs. 78%) than those in the control group (P<.001). Adjustment for age and sex reduced but did not eliminate the significance of this difference (P=.01). Patients with PSC reported consuming an average of 50 cups of coffee per month and having been active coffee drinkers for 50% of their lives, while controls reported consuming 78 cups per month and actively consuming coffee for 67% of their lives (P<.01).
No significant difference was observed between patients with PBC and controls with regard to their estimated lifetime consumption per month, the percentage of their lives spent as active coffee drinkers, and the mean age at which participants began consuming coffee. The percentages of those reporting current coffee consumption and having never consumed coffee also were not significantly different between the groups.
“Our data showed that coffee consumption over a lifetime was associated with reduced risk of PSC, but not PBC,” Lammert said here. “… This association with PSC but not PBC likely has very important implications for future studies. … We think these diseases are much more different than we originally thought; moving forward, we can look at what this finding may tell us about the causes of these diseases, and how to better treat them, and also give some feedback to patients as potentially modifiable risk factors.”
Lammert C. #630: Coffee Consumption is Associated with Reduced Risk of Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. Presented at: Digestive Disease Week; May 18-21, Orlando.